Last reviewed · How we verify
vitamin A and E
Vitamin A and E, marketed by Cairo University, holds a position in the nutritional supplement market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and broad acceptance in the market. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | vitamin A and E |
|---|---|
| Sponsor | Cairo University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1 (NA)
- Comparing Dual-mobility Cups Versus Unipolar Cups for Unselected Primary Total Hip Arthroplasty by Direct Anterior Approach (NA)
- Structured Review: To Optimise Management and Prevent Harm in COPD (NA)
- Postpartum Vaginal Estrogen for Breastfeeding Patients (PHASE4)
- Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI (PHASE1)
- A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vitamin A and E CI brief — competitive landscape report
- vitamin A and E updates RSS · CI watch RSS
- Cairo University portfolio CI